Effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis: a preliminary report of real-world data

Ital J Dermatol Venerol. 2022 Apr;157(2):211-213. doi: 10.23736/S2784-8671.21.07014-6.

Authors

Silvia M Ferrucci¹, Carlo A Maronese^{2

3}, Simona Tavecchio¹, Luisa Angileri¹, Giovanni Genovese^{1

3}, Angelo V Marzano^{1

3}

Affiliations

¹ Unit of Dermatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
² Unit of Dermatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy - [email protected].
³ Department of Physiopathology and Transplantation, University of Milan, Milan, Italy.

PMID: 35391535
DOI: 10.23736/S2784-8671.21.07014-6

No abstract available

MeSH terms

Adolescent
Antibodies, Monoclonal, Humanized / adverse effects
Dermatitis, Atopic* / drug therapy
Humans
Severity of Illness Index

Substances

Antibodies, Monoclonal, Humanized
dupilumab